LON:AGY - Allergy Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 19.50
+0 (0.00%)

This chart shows the closing price for AGY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Allergy Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGY

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Allergy Therapeutics in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a -100.00% upside from the last price of GBX 19.50.

This chart shows the closing price for AGY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Allergy Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/15/2020FinnCapReiterated RatingCorporate
7/9/2020FinnCapReiterated RatingCorporate
6/24/2020FinnCapReiterated RatingCorporate
3/4/2020FinnCapReiterated RatingCorporate
2/3/2020FinnCapReiterated RatingCorporate
1/16/2020FinnCapReiterated RatingCorporate
11/28/2019FinnCapReiterated RatingCorporate
9/25/2019FinnCapReiterated RatingCorporate
7/11/2019FinnCapReiterated RatingCorporate
6/28/2019FinnCapReiterated RatingCorporate
4/29/2019FinnCapReiterated RatingCorporate
3/22/2019FinnCapLower Price TargetCorporateGBX 47 ➝ GBX 40
3/18/2019Numis SecuritiesReiterated RatingBuyGBX 35
3/6/2019Numis SecuritiesReiterated RatingBuyGBX 45
3/6/2019FinnCapReiterated RatingCorporate
1/16/2019FinnCapReiterated RatingCorporate
9/27/2018FinnCapReiterated RatingCorporate
9/26/2018Numis SecuritiesReiterated RatingBuyGBX 45
7/19/2018Numis SecuritiesReiterated RatingBuy
7/12/2018FinnCapReiterated RatingCorporate
5/21/2018Numis SecuritiesReiterated RatingBuy
5/21/2018FinnCapReiterated RatingCorporate
3/7/2018Numis SecuritiesReiterated RatingBuyGBX 45
3/7/2018FinnCapReiterated RatingCorporateGBX 47
2/28/2018FinnCapReiterated RatingCorporateGBX 47
2/12/2018FinnCapReiterated RatingCorporateGBX 47
2/1/2018FinnCapReiterated RatingCorporateGBX 47
1/31/2018Numis SecuritiesReiterated RatingBuyGBX 45
12/5/2017Numis SecuritiesReiterated RatingBuyGBX 45
11/21/2017FinnCapReiterated RatingBuyGBX 47
10/20/2017FinnCapReiterated RatingBuyGBX 47
9/28/2017Panmure GordonReiterated RatingBuy
9/28/2017Numis SecuritiesReiterated RatingBuyGBX 45
9/28/2017FinnCapBoost Price TargetBuyGBX 46 ➝ GBX 47
9/22/2017Numis SecuritiesReiterated RatingBuyGBX 45
9/18/2017Panmure GordonReiterated RatingBuy
8/24/2017FinnCapReiterated RatingBuyGBX 46
7/18/2017Numis SecuritiesReiterated RatingBuyGBX 45
7/18/2017FinnCapBoost Price TargetBuyGBX 43 ➝ GBX 46
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Allergy Therapeutics logo
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Read More

Today's Range

Now: GBX 19.50
Low: 19
High: 19.65

50 Day Range

MA: GBX 21.57
Low: 19.12
High: 23.63

52 Week Range

Now: GBX 19.50
Low: 19
High: 40.50

Volume

45,079 shs

Average Volume

166,542 shs

Market Capitalization

£125.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Allergy Therapeutics?

The following Wall Street sell-side analysts have issued reports on Allergy Therapeutics in the last year:
View the latest analyst ratings for AGY.

What is the current price target for Allergy Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Allergy Therapeutics in the last year.
View the latest price targets for AGY.

What is the current consensus analyst rating for Allergy Therapeutics?

Allergy Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AGY.

How do I contact Allergy Therapeutics' investor relations team?

Allergy Therapeutics' physical mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company's listed phone number is +44-1903-844700. The official website for Allergy Therapeutics is www.allergytherapeutics.com. Learn More about contacing Allergy Therapeutics investor relations.